FINWIRES · TerminalLIVE
FINWIRES
$PFE

$PFE

49 stories mentioning PFEUpdated 20d ago

Every FINWIRES story that references PFE, newest first.

Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.8%.The iShares Biotechnology ETF (IBB) fell 2.6%.In corporate news, Bausch + Lomb (BLCO) shares fell 2.9%. The company said late Thursday that results from a phase 2 trial assessing BL1107 in people with glaucoma showed the study did not meet its primary endpoint of replicating visual function improvements seen in a smaller phase 1/2a trial.Pfizer's (PFE) Q2 revenue is expected to match Wall Street's estimates, but its EPS may fall short, RBC said in a note. Separately, Pfizer's vaccine disputes with Poland and Romania continue, now extending to the countries' air traffic agencies, Bloomberg reported. Pfizer shares were fractionally higher.SL Science (SLBT) shares gained 4.4% after it said Friday it has submitted an orphan drug designation request to the US Food and Drug Administration for its Gamma Delta T therapy, named Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme.Cosmos Health (COSM) shares jumped 15% after it said Friday that it has launched a subscription-based purchasing model for its consumer health brands.

$BLCO$COSM$PFE$SLBT
Wire

Sector Update: Healthcare Stocks Decline Friday Afternoon

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 1%.The iShares Biotechnology ETF (IBB) fell 2.7%.In corporate news, Bausch + Lomb (BLCO) shares fell 3.5%. The company said late Thursday that results from a phase 2 trial assessing BL1107 in people with glaucoma showed the study did not meet its primary endpoint of replicating visual function improvements seen in a smaller phase 1/2a trial.Pfizer's (PFE) Q2 revenue is expected to match Wall Street's estimates, but its EPS may fall short, RBC said in a note. Separately, Pfizer's (PFE) vaccine disputes with Poland and Romania continue, now extending to the countries' air traffic agencies, Bloomberg reported. Pfizer shares were up 0.1%.Cosmos Health (COSM) shares jumped 10% after it said Friday that it has launched a subscription-based purchasing model for its consumer health brands.

$BLCO$COSM$PFE
Sectors

Sector Update: Healthcare

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 1%.The iShares Biotechnology ETF (IBB) fell 2.9%.In corporate news, Pfizer's (PFE) Q2 revenue is expected to match Wall Street's estimates, but its EPS may fall short, RBC said in a note. Pfizer shares were fractionally higher.

$PFE
Wire

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday.Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) remain its top picks.Bank of America raised its price targets on AbbVie to $276 from $234, Johnson & Johnson (JNJ) to $263 from $254 and Eli Lilly to $1,334 from $1,251.The analysts lowered targets on Bristol Myers Squibb (BMY) to $66 from $67, Pfizer (PFE) to $26 from $27 and United Therapeutics (UTHR) to $613 from $620.Price: $123.45, Change: $-1.63, Percent Change: -1.30%

$ABBV$BMY$IONS$JAZZ$JNJ$LLY$MRK$PFE$UTHR
Pfizer Poised for Mixed Second Quarter, RBC Says
US Markets

Pfizer Poised for Mixed Second Quarter, RBC Says

Pfizer's (PFE) second-quarter revenue is expected to match Wall Street's estimates, while its earnings per share may fall short, RBC Capital Markets said in a note on Friday.The brokerage forecasts revenue of $14.43 billion, largely in line with consensus views, with EPS at $0.66, lower than the Street's $0.68 estimate.The drugmaker is scheduled to report its second-quarter financials Aug. 4.Pfizer COVID-19 products Comirnaty and Paxlovid are expected to generate lower-than-expected revenue for the second quarter amid waning demand for vaccinations, RBC analyst Trung Huynh wrote. Prostate cancer drug Xtandi will also likely miss consensus estimates, though Eliquis and Ibrance are seen coming in stronger than expected.Xtandi is co-developed by Pfizer and Astellas Pharma. Eliquis is a blood thinner medicine jointly developed by Bristol Myers Squibb (BMY) and Pfizer, while Ibrance is Pfizer's breast cancer treatment."Our EPS sits 3% below consensus due to unfavorable gross margin mix and elevated (research and development) spending to fund key pipeline programs," according to the RBC note.RBC raised its 2026 revenue forecast to $61.33 billion from $61.25 billion and trimmed the adjusted EPS estimate to $2.86 from $2.90. In May, Pfizer maintained its 2026 guidance, including sales at $59.5 billion to $62.5 billion and earnings of $2.80 to $3 per share."Based on prescription data analysis, we have lower confidence in a (second-quarter) guidance raise and have reduced our 2026 estimates by (1% to 2%), now placing us in the lower half of guidance," Huynh wrote.RBC maintained its sector perform rating on the Pfizer stock, with a $25 price target.Last month, Pfizer named Cecile Guegan interim chief financial officer as Dave Denton prepared to join Nike (NKE) as finance chief. RBC said Pfizer expects to appoint a permanent CFO by the end of 2026.Price: $24.23, Change: $-0.02, Percent Change: -0.10%

$PFE
Wire

BofA Securities Adjusts Pfizer Price Target to $26 From $27

Pfizer (PFE) has an average rating of hold and mean price target of $28.62, according to analysts polled by FactSet.Price: $24.39, Change: $+0.14, Percent Change: +0.56%

$PFE
Wire

Update: Market Chatter: AstraZeneca Wins Pfizer Patent Battle Over Cancer Drug

(Updates with AstraZeneca declining to comment in paragraph three).AstraZeneca (AZN) won a lawsuit filed in 2021 by Pfizer (PFE) after a US appeals court upheld a ruling in favor of the drugmaker over allegations that its lung-cancer drug Tagrisso infringed patents, Reuters reported Thursday.The Washington-based US Court of Appeals for the Federal Circuit agreed with a Delaware federal judge that the two patents at the center of the dispute, owned by Pfizer's subsidiary Wyeth, were invalid.AstraZeneca declined to comment, while Pfizer did not immediately respond to' request for comment.AstraZeneca shares were down more than 5% in recent afternoon trading.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $178.88, Change: $-10.41, Percent Change: -5.50%

$AZN$PFE
Wire

Market Chatter: AstraZeneca Wins Pfizer Patent Battle Over Cancer Drug

AstraZeneca (AZN) won a lawsuit filed in 2021 by Pfizer (PFE) after a US appeals court upheld a ruling in favor of the drugmaker over allegations that its lung-cancer drug Tagrisso infringed patents, Reuters reported Thursday.The Washington-based US Court of Appeals for the Federal Circuit agreed with a Delaware federal judge that the two patents at the center of the dispute, owned by Pfizer's subsidiary Wyeth, were invalid.AstraZeneca and Pfizer did not immediately respond to' request for comment.AstraZeneca shares were down more than 5% in recent afternoon trading.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $179.49, Change: $-9.79, Percent Change: -5.17%

$AZN$PFE
Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
US Markets

Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says

Major US biopharmaceutical companies' performance in the second half of the year is likely to be driven largely by fundamentals, as the focus shifts away from economic factors, Morgan Stanley said in a note e-mailed Wednesday.The investment firm revised its price targets for several biopharma stocks it covers ahead of the latest earnings season."The macro has been a key driver of large-cap biopharma performance over the first half of the year," the brokerage said in a note to clients. "Looking into the second half, we expect fundamentals to be more of a driver. We prefer stocks with upside from product cycles and/or pipeline catalysts."Morgan Stanley raised its price target for Eli Lilly (LLY) to $1,347 from $1,344. It expects second-quarter earnings per share of $9.06 for the pharmaceutical giant, compared with Wall Street's estimate of $8.80. The firm projects revenue of $20.78 billion, while the Street is looking for $20.47 billion.The firm expects Johnson & Johnson (JNJ) to deliver a second-quarter beat, with EPS projected at $2.90 and sales at $25.46 billion. Morgan Stanley raised its price target on the stock to $284 from $283.Pfizer's (PFE) second-quarter EPS is seen at $0.69, while the Street is looking for $0.68, according to the note. Revenue is projected at $14.29 billion, while the Street is eyeing $14.44 billion.Moderna's (MRNA) new price target is $39, up from $33 previously. The drugmaker is expected to report a second-quarter loss of $1.85 a share on revenue of $172 million versus the Street's views for a $2.06 loss and sales of $102 million, according to Morgan Stanley.The price target for the Abbvie (ABBV) stock moved to $279 from $278, with Morgan Stanley expecting the company's second-quarter revenue to be ahead of consensus and guidance at $16.88 billion, while EPS is seen at $3.71 versus the Street's forecast of $3.76.Morgan Stanley lowered its price target for Gilead Sciences (GILD) to $166 from $168. The brokerage is projecting a second-quarter loss per share at $7.34, while the Street is looking for a $7.31 loss. Revenue is expected at $7.36 billion, below the $7.41 billion consensus, according to the note.Price: $1228.54, Change: $-7.02, Percent Change: -0.57%

$ABBV$GILD$JNJ$LLY$MRNA$PFE
Nike Fourth-Quarter Revenue Slips as Expected Tariff Refunds Boost Earnings
US Markets

Nike Fourth-Quarter Revenue Slips as Expected Tariff Refunds Boost Earnings

Nike's (NKE) fiscal fourth-quarter revenue slipped year-over-year, while the sportswear company's earnings got a boost from expected tariff refunds.Revenue fell 1% to $10.97 billion for the quarter ended May 31, topping the FactSet-polled consensus of $10.85 billion. Earnings per share soared 414% to $0.72, driven by a $0.52 benefit related to the expected recovery of trade tariffs.The US Supreme Court in February invalidated President Donald Trump's reciprocal tariffs imposed under the International Emergency Economic Powers Act."We delivered fourth-quarter results in line with our expectations, demonstrating financial discipline in an increasingly challenging operating environment, where sell-through remains challenged," Chief Financial Officer Matthew Friend said in a statement.The stock fell 4.3% in after-hours trade, and is down 36% this year through Tuesday close.Revenue for the Nike brand was virtually flat at $10.72 billion, weighed down by a 12% drop in China. North American sales grew 3%, while Europe, the Middle East and Africa fell 1%.Consolidated equipment and footwear revenue for the Nike brand declined.Chief Executive Elliott Hill acknowledged the company continues to face top-line headwinds, but said it remains focused on "consistent execution" and profitability.Macro pressures and internal challenges were expected to drive a soft quarterly performance at Nike, Oppenheimer said Friday. The brokerage said 2026 is shaping up to be a restructuring year for Nike and recommended staying on the sidelines until there's more visibility into a broader recovery.Last week, Nike said David Denton will join the company as chief financial officer in August, succeeding Friend. Denton has served as CFO of Pfizer (PFE) since May 2022.

$NKE$PFE
Wire

Pfizer Keeps Quarterly Dividend at $0.43 per Share, Payable Sept. 1, to Shareholders of Record July 24

Pfizer Keeps Quarterly Dividend at $0.43 per Share, Payable Sept. 1, to Shareholders of Record July 24

$PFE
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.9%.The iShares Biotechnology ETF (IBB) climbed 2.4%.In corporate news, Eli Lilly (LLY) and Bayer's pharmaceutical division have backed the Trump administration's call for higher drug prices in Europe, the Financial Times reported. Separately, Lilly said Wednesday it has completed its acquisition of Centessa Pharmaceuticals. Lilly shares were up 0.6%.NRx Pharmaceuticals (NRXP) and two units are facing a lawsuit from Kadima Neuropsychiatry Institute for alleged breach of contract and misrepresentation regarding an acquisition agreement, the psychiatric clinic said Wednesday. NRx Pharmaceuticals shares fell 12%.Pfizer (PFE) has been dismissed as a defendant in a lawsuit brought by 45 US states, the District of Columbia, and 4 US territories that accused drugmakers and executives of fixing generic drug prices, Reuters reported. Its shares were down 2.4%.InMode (INMD) board received an unsolicited acquisition proposal last week for all shares not already owned by M.N. Business Strategy for $16.20 per share in cash, the medical technology firm said Wednesday. The shares jumped 10%.

$INMD$LLY$NRXP$PFE
Wire

Update: Market Chatter: Pfizer Dismissed From US States' Lawsuit on Generic Drug Price Fixing

(Updates with Pfizer's response in the last two paragraphs.)Pfizer (PFE) has been dismissed as a defendant in a lawsuit brought by 45 US states, the District of Columbia, and 4 US territories that accused drugmakers and executives of fixing generic drug prices, Reuters reported Wednesday, citing a court decision.Michael Shea, Chief Judge of the federal district court in Connecticut, said in a Tuesday ruling the states failed to establish that Pfizer and its former Greenstone unit colluded with competitors to rig bids and allocate customers for drug products, according to the report."Pfizer is pleased with the Court's decision to grant summary judgment and dismiss all claims against Pfizer- which had no involvement in the alleged conduct and should never have been named in the complaint to begin with", a Pfizer spokesperson said in an emailed statement to.Pfizer is pleased with the Court's prior decision to reduce the claims against Greenstone, the spokesperson said, adding that the company believes the remaining claims are without merit and will continue to vigorously defend against these claims.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $24.08, Change: $-0.65, Percent Change: -2.61%

$PFE
Sectors

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) climbed 2.2%.In corporate news, InMode (INMD) board received an unsolicited acquisition proposal last week for all shares not already owned by M.N. Business Strategy for $16.20 per share in cash, the medical technology firm said Wednesday. Shares jumped 11%.Pfizer (PFE) has been dismissed as a defendant in a lawsuit brought by 45 US states, the District of Columbia, and 4 US territories that accused drugmakers and executives of fixing generic drug prices, Reuters reported. Shares were down 3.1%.Eli Lilly (LLY) and Bayer's pharmaceutical division have backed the Trump administration's call for higher drug prices in Europe, the Financial Times reported. Separately, Lilly said Wednesday it has completed its acquisition of Centessa Pharmaceuticals. Lilly shares were shedding 0.5%.

$INMD$LLY$PFE
Wire

Market Chatter: Pfizer Dismissed From US States' Lawsuit on Generic Drug Price Fixing

Pfizer (PFE) has been dismissed as a defendant in a lawsuit brought by 45 US states, the District of Columbia, and 4 US territories that accused drugmakers and executives of fixing generic drug prices, Reuters reported Wednesday, citing a court decision.Michael Shea, Chief Judge of the federal district court in Connecticut, said in a Tuesday ruling the states failed to establish that Pfizer and its former Greenstone unit colluded with competitors to rig bids and allocate customers for drug products, according to the report.Pfizer did not immediately respond to a request for comment by.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $24.13, Change: $-0.59, Percent Change: -2.39%

$PFE
Wire

Pfizer's Palbociclib Combination Therapy Gets FDA Approval for Certain Types of Breast Cancer

Pfizer's (PFE) palbociclib, in combination with trastuzumab, with or without pertuzumab, and endocrine therapy has received the US Food and Drug Administration's approval as a maintenance treatment for adults with HR-positive, HER-2 positive locally advanced or metastatic breast cancer, the regulator said Wednesday.The recommended dosage for the drug is 125mg orally once a day for 21 days, followed by seven days off treatment to complete a 28-day cycle.Palbociclib received breakthrough therapy designation, the FDA said.Price: $24.27, Change: $-0.45, Percent Change: -1.84%

$PFE
Pfizer Names Interim Finance Chief as CFO Quits; Drugmaker Affirms Full-Year Outlook
US Markets

Pfizer Names Interim Finance Chief as CFO Quits; Drugmaker Affirms Full-Year Outlook

Pfizer (PFE) named an interim head of finance on Thursday as it announced the departure of Chief Financial Officer Dave Denton.Cecile Guegan, the US drugmaker's senior vice president of finance for the global biopharmaceutical business, will serve as interim CFO, beginning Aug. 16, Pfizer said in a statement. Guegan has been with Pfizer for more than 20 years.Denton will leave the company on Aug. 15, having accepted an opportunity in the consumer goods industry, Pfizer said.Separately, the company affirmed its fiscal 2026 guidance, according to a regulatory filing.It continues to expect full-year adjusted per-share earnings of $2.80 to $3 and revenue between $59.5 billion to $62.5 billion. Analysts in a FactSet poll are looking for non-GAAP EPS of $2.96 on sales of $61.74 billion.Pfizer previously reported 2025 adjusted EPS of $3.22 and revenue of $62.58 billion.Last month, Pfizer posted higher-than-expected first-quarter results as robust demand across its key brands offset weakening sales of its COVID-19 products.Shares of Pfizer were down 2.7% in late afternoon trade on Thursday. The stock is up 1.3% so far this year.Price: $25.29, Change: $-0.64, Percent Change: -2.45%

$PFE
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks fell late Thursday afternoon with the NYSE Healthcare Index dropping 1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.9%.The iShares Biotechnology ETF (IBB) shed 0.3%.In corporate news, Pfizer (PFE) shares dropped 2.5% after the company reaffirmed its fiscal 2026 guidance. The company also said Chief Financial Officer Dave Denton will step down on Aug. 15 after accepting a position in the consumer-goods sector.Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion. Biogen shares fell 1.4%.EnGene (ENGN) shares shed 1.4% after Morgan Stanley downgraded the stock to underweight from equalweight.NovoCure (NVCR) shares tumbled 19% after the company said a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.

$BIIB$ENGN$NVCR$PFE
Sectors

Sector Update: Healthcare

Healthcare stocks fell late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.7%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Pfizer (PFE) shares fell 2.5% after the company reaffirmed its fiscal 2026 guidance in a regulatory filing. Pfizer also said Chief Financial Officer Dave Denton will step down on Aug. 15 after accepting a position in the consumer-goods sector.

$PFE
Wire

Pfizer Shares Fall After Reaffirming Fiscal 2026 Guidance

Pfizer (PFE) shares fell 2.6% in Thursday trading after the company reaffirmed its fiscal 2026 guidance in a regulatory filing.The company continues to expect fiscal 2026 adjusted earnings of $2.80 to $3.00 per diluted share and revenue range of $59.5 billion to $62.5 billion, according to the filing with the US Securities and Exchange Commission.Analysts surveyed by FactSet expect $2.96 and $61.74 billion, respectively.Price: $25.25, Change: $-0.67, Percent Change: -2.58%

$PFE

Showing 1-20 of 49

Track with the FINWIRES app suite

FolioX
FolioX
Track PFE in your portfolio
WheelAI
WheelAI
Analyze PFE options with the wheel strategy
StockInsider
StockInsider
See market sentiment on PFE